BioTuesdays - Sucampo sees revenue from three continents by year end
Sucampo Pharmaceuticals (NASDAQ:SCMP) expects to be generating revenue from three continents – North America, Europe and Asia – by the end of 2013 from its two approved prostones products, Amitiza for gastrointestinal diseases and Rescula for ophthalmics.
“This is in line with our goal to be a global company,” CFO Cary Claiborne says in an interview with BioTuesdays. “We are the only company developing and commercializing prostone compounds globally.”
Prostones are functional fatty acid metabolites that occur naturally in the body. Prostones work as selective ion channel activators, promoting fluid secretion, enhancing cell protection and acting locally to restore normal function in cells and tissues.
See Bio Tuesdays for rest of feature article posted this morning.